MedTrace Logo

Irinotecan Drug-eluting Bead Liver Embolisation Registry

NCT03697044 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2018-10-05

No results posted yet for this study

Summary

Purpose:

The purpose of this study is: to assess and define the current practice of the delivery of irinotecan loaded drug eluting beads in the treatment of liver metastases from colorectal cancer; to correlate how the delivery of this drug compares to worldwide/European guidelines, and to determine which individual variations in delivery may be associated with an increased complication profile or better outcome.

The aim of the study is to:

1. Prospectively evaluate the number of centres providing DEBIRI
2. To determine the number of patients being treated nationally per year
3. To evaluate individual variations in practice with respect to number of treatments, method of pain control, side effect profile, and complication profile.
4. To collect patient specific data subsets to allow correlation and causal associations between these individual variations, and relate these to efficacy and survival during the study period.

Conditions

  • Colorectal Cancer Metastatic
  • Liver Metastases

Interventions

PROCEDURE

Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation

Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.

Sponsors & Collaborators

  • The Christie NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2023-01-31
Completion
2024-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697044 on ClinicalTrials.gov